PeopleWith is a free health-tracking app for patients to log symptoms, medications, and vital signs on iOS and Android.
Product velocity
Active
Daily rank 🇺🇸
—
Medical
Sentiment
1.5
2 reviews
Nemesis
Migraine Buddy: Track Headache
The App DNA
What makes this app unique?
Users hire the app to generate structured health evidence for clinical appointments, but the current crash-prone state prevents the job-to-be-done.
For Patients and carers managing chronic or acute health conditions who need to track symptoms and medication for clinical review.
What does it look like?
Key features
Logs symptom intensity and triggers to generate evidence for healthcare professionals
Generates consolidated health documents for sharing with medical providers
Schedules and tracks medication adherence with automated alerts
How much does it cost?
The app operates on a zero-cost model for patients, shifting monetization to B2B data services and life science industry partnerships.
Velocity
Active developmentShow more...
5 versions in history. Development pace: active.
Who built it?
mymind
3 apps tracked · Medical
User Sentiment
What do users think recently?
Fresh user feedback skews frustrated.
How are ratings & reviews evolving?
What users say, by theme
- Application crashes occur consistently when users attempt to access the symptoms tracking section
1 of 1 recent reviews analyzed · limited sample
Read the full review analysisCompetition
Competitive landscape for PeopleWith - Symptoms & Health
How's the Medical market?
PeopleWith maintains a low-visibility profile with only 2 total ratings on iOS and 0 on Android. The zero-price model attempts to capture users from paid competitors, but the lack of stability prevents market share acquisition.
Read the market outlookThe rivals identified
By Voluntis
Dominates the symptom-specific tracking niche with a massive, highly-engaged user base and specialized longitudinal health reporting.
- Specialized migraine-specific triggers and weather-correlation tracking provides deeper clinical insights than general symptom logs.
- Integrated PDF report generation allows users to share structured health data directly with their primary care physicians.
- Community-driven support forums provide peer-to-peer validation that general health trackers lack.
Unlock the head-to-head verdict: where this rival wins, and where it loses.
Access the full report for freeThe Analyst's Read
Key takeaways for PeopleWith - Symptoms & Health
Where is it heading?
The health-tracking market is consolidating around specialized, stable tools that provide immediate clinical feedback. PeopleWith remains exposed due to its inability to maintain basic app functionality, which will continue to erode its rating and prevent the scale needed for its B2B data model.
- Persistent crashes in the symptoms module block the primary value proposition, leading to a 1.5★ rating that discourages new user acquisition.
- Recent updates focused on interface refinements and registration speed, but these improvements are overshadowed by the underlying stability failure.
The SWOT
- Zero-cost model removes monetization friction
- Anonymity-first data policy builds patient trust
- Life science industry data partnerships
- Expanded vital sign clinical integrations
Next best moves
Rebuild symptom module stability because it is the #1 churn driver → restore core utility
+ 1 more prioritized moveThe counter-intuitive read
The app's lack of monetization is a liability, not an asset…
Read the full takeFeature gaps
Specialized migraine-specific triggers (available in Migraine Buddy) +2
Since the last report: The app has transitioned from a functional health tracker to a high-risk product due to critical stability failures in the symptom-tracking module, despite the addition of medication reminder features.
Bottom line
PeopleWith offers a compelling free alternative to paid health trackers, but the persistent symptoms-module crash destroys user trust, so the team must prioritize stability over feature expansion to prevent total churn.
Unlock 3 critical frictions, 2 market threats, 1 more prioritized move and the analyst’s take.
Access the full report for freeReport last updated